Moderna (NASDAQ: MRNA) shares reversed an early 9.6% premarket gain on Friday, despite the vaccine maker reporting better-than-expected third-quarter earnings and raising its 2026 revenue growth forecast to 15%–25%, from a previous outlook of up to 10%.
The stock initially climbed to $264.79 after the earnings announcement but later fell to $239.85, down 0.67% from Thursday’s close of $241.46.
The premarket reversal followed two volatile sessions. Moderna shares gained 13.11% on Wednesday before dropping 6.55% on Thursday, when the stock hit a 52-week intraday high of $261 during regular trading.
Moderna shares had risen more than eightfold in 2026, with much of the rally coming after the company and Merck announced positive late-stage results for their experimental personalized melanoma vaccine in August.
#CryptoNewsFlash
The stock initially climbed to $264.79 after the earnings announcement but later fell to $239.85, down 0.67% from Thursday’s close of $241.46.
The premarket reversal followed two volatile sessions. Moderna shares gained 13.11% on Wednesday before dropping 6.55% on Thursday, when the stock hit a 52-week intraday high of $261 during regular trading.
Moderna shares had risen more than eightfold in 2026, with much of the rally coming after the company and Merck announced positive late-stage results for their experimental personalized melanoma vaccine in August.
#CryptoNewsFlash